Nanobiotix to host virtual KOL event discussing potential first-in-class radioenhancer NBTXR3 in immunotherapy on june 11, 2021

Paris, France; Cambridge, Massachusetts (USA); June 7, 2021  –  NANOBIOTIX  (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL event for analysts, investors, and the scientific community on Friday, June 11, 2021 at 8AM ET / 2PM CET. The event will feature several key opinion leaders, including current study investigators. The Nanobiotix KOL event will provide an in-depth review of the immunotherapy data presented at the 2021 Annual Meeting of American Society for Clinical Oncology (ASCO) along with clinical perspectives on the implications of potential first-in-class radioenhancer NBTXR3 across the oncology landscape. Registration for the event is now open on the  events section  of the Company’s website. A live webcast of the discussion and an archived recording will be available on the events section as well. Nanobiotix Virtual KOL Event Program Can NBTXR3 Turn Anti-PD-1 Non-responders into Responders and Deepen Response in Naïve Patients? Agenda Opening Remarks (8:00AM ET / 2:00PM CET) Presented by Jeffrey Bockman, PhD, EVP and Oncology Practice Head, Cello Health BioConsulting NBTXR3 Mode of Action (8:05AM ET / 2:05PM CET) Presented by Laurent Levy, PhD, co-founder and CEO, Nanobiotix  Overview of the Treatment Landscape: Promise and Limitations of Immunotherapy, and Rationale for Combination-based Approaches (8:10AM ET / 2:10PM CET) Presented by Jared Weiss, MD, Associate Professor of Medicine, Division of Oncology, University of North Carolina Lineberger Comprehensive Cancer Center Nanobiotix Study 1100 Safety and Efficacy Data Update (8:20AM ET / 2:20PM CET) Presented by Tanguy Seiwert, MD, Assistant Professor of Oncology, Director, Head and Neck Cancer Oncology Disease Group, Johns Hopkins Medicine and Colette Shen, MD, PhD, Assistant Professor, Radiation Oncology, University of North Carolina Lineberger Comprehensive Cancer Center NBTXR3 as a Potential Combination-agnostic Product, Rationale, and Future Opportunity (8:40AM ET / 2:20PM CET) Presented by James Welsh, MD, Associate Professor, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center Discussion and Q&A, Implications of Study 1100 in Head and Neck Cancer and Beyond (8:50AM ET / 2:50PM CET) Panel Discussion Moderated by Jeffrey Bockman  Summary Close (9:10AM ET / 3:10PM CET Presented by Jeffrey Bockman About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, Germany and Switzerland. Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate– NBTXR3 —which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®. For more information about Nanobiotix, visit us at  www.nanobiotix.com  or follow us on  LinkedIn  and  Twitter . View source version on  businesswire.com :  https://www.businesswire.com/news/home/20220104005866/en/ Nanobiotix Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 [email protected] Investor Relations Department Kate McNeil SVP, Investor Relations +1 (609) 678-7388 [email protected] Media Relations France –  Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79 97 51 [email protected] US –  Porter Novelli Dan Childs +1 (781) 888-5106 [email protected] Source: Nanobiotix

The release as fetched from its publisher. nanobiotix.com ↗